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Abstract
The nuclear receptors REV-ERBα (encoded by NR1D1) and REV-ERBβ (NR1D2) have remained
orphans owing to the lack of identified physiological ligands. Here we show that heme is a
physiological ligand of both receptors. Heme associates with the ligand-binding domains of the REV-
ERB receptors with a 1:1 stoichiometry and enhances the thermal stability of the proteins. Results
from experiments of heme depletion in mammalian cells indicate that heme binding to REV-ERB
causes the recruitment of the co-repressor NCoR, leading to repression of target genes including
BMAL1 (official symbol ARNTL), an essential component of the circadian oscillator. Heme extends
the known types of ligands used by the human nuclear receptor family beyond the endocrine
hormones and dietary lipids described so far. Our results further indicate that heme regulation of
REV-ERBs may link the control of metabolism and the mammalian clock.
REV-ERBα was originally identified as an orphan member of the nuclear hormone receptor
(NHR) family on the basis of its canonical domain structure and sequence conservation1,2.
REV-ERBβ was subsequently identified by its homology to other NHRs and its pattern of
expression, which overlaps greatly with that of REV-ERBα. Both receptors have particularly
high expression in the liver, adipose tissue, skeletal muscle and brain3–8, where they are
transcribed in a circadian manner9–11. The REV-ERBs are unique in the NHR superfamily in
that they lack the carboxy-terminal tail (helix 12) of the ligand-binding domain (LBD), which
is required for coactivator recognition12 (Supplementary Fig. 1a online). Both receptors act as
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constitutive repressors of transcription and bind DNA response elements termed ‘ROREs’13–
15. Although considerably more is known about the function of REV-ERBα than that of REV-
ERBβ, the similarities in their expression patterns and DNA-binding and transcriptional
activities indicate that they are likely to overlap substantially in function. Nevertheless, more
complete understanding of their functional properties has been hindered by the lack of known
physiological ligands.
REV-ERBα is a principal regulator of the cyclic expression of BMAL1 (refs. 16–18), a key
component of the mammalian circadian clock. Circadian rhythms play an essential part in
aspects of physiology and behavior, including the sleep-wake cycle, body temperature, blood
pressure and renal function. The circadian rhythms are generated by feedback loops in gene
expression in which heterodimers of BMAL1 and CLOCK activate expression of the
cryptochrome (Cry) and period (Per) genes (the negative limb)19,20. When CRY and PER
reach a critical level of expression, they block the stimulatory effect of the CLOCK or NPAS2–
BMAL1 complex on their own genes, thereby completing the loop20,21. The BMAL1 promoter
contains two ROREs, and BMAL1 transcription is directly repressed by REV-ERBα16,22. Mice
deficient in NR1D1, the gene encoding REV-ERBα, show loss of the diurnal pattern of
expression of BMAL1 and alterations in the period and phase of their circadian behavior
patterns17.
Clues to a possible physiological ligand for the REV-ERB proteins has come from a study on
E75, a member of the NHR family in Drosophila that has been shown to contain a heme
prosthetic group23. The oxidation state of iron-heme in E75 determines whether this NHR can
interact with its heterodimer partner, DHR3, and this dimer interaction is further regulated by
binding of either nitric oxide or carbon monoxide to heme23. The heme in E75 is highly resistant
to dissociation, and its forcible removal produces an unstable protein23,24. Thus, heme could
be involved in the regulation of E75 activity by influencing its stability, or by functioning as
a sensor of redox and/or diatomic gases23. Alignment of the LBDs of E75 and the REV-ERB
receptors shows good conservation overall (Supplementary Fig. 1b). Because heme
concentrations change in a circadian manner and can entrain the mammalian clock25,26 and
because heme is used as a cofactor by proteins that control metabolic functions and the circadian
clock including NPAS2 (ref. 27), we have examined whether the human REV-ERB nuclear
receptors use heme as their ligand.
RESULTS
REV-ERB proteins are associated with heme
We purified recombinant histidine-tagged human REV-ERBα and REV-ERBβ LBD proteins
after expression in Escherichia coli. We also prepared Flag-tagged full-length REV-ERBα and
REV-ERBβ by transient transfection of human embryonic kidney HEK293 cells. Both cell
systems are known to produce heme that associates with heme-binding proteins28,29, and
recombinant E75 protein expressed in E. coli has been shown to associate tightly with
heme23.
Both full-length receptors and LBDs were extensively purified, and the samples were notably
red or pink in color (Supplementary Fig. 2 online). Matrix-assisted laser desorption-ionization
(MALDI) mass spectra of these samples showed a heme peak, corresponding to iron-
protoporphyrin IX, with the expected mass of 616 ± 2 Da (mean ± s.d.; Fig. 1a and
Supplementary Fig. 3 online). The distinct features of heme bound to the proteins were
observed by ultraviolet-visible spectroscopy: namely α and β peaks in the 500–600 nm range
and γ (Soret) peaks in the 390–450 nm range (Fig. 1b and Supplementary Fig. 4 online). In
addition, the associated heme was in the oxidized state because the Soret peak was shifted on
addition of the reducing agent dithionite (Fig. 1b).
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Heme binding thermodynamics
To characterize the thermodynamics of heme binding to REV-ERB proteins, we used
isothermal titration calorimetry (ITC) after removing heme from the purified LBDs. In contrast
to Drosophila melanogaster E75, heme can be removed from the REV-ERB LBDs by extensive
washing of Ni-NTA–immobilized proteins or through dialysis (Supplementary Fig. 5 online).
Heme-depleted receptors were appropriately folded and fully competent to bind exogenously
added heme, as shown by the ITC measurements; both REV-ERB LBDs bound to heme with
a dissociation constant (Kd) of 2–3 μM (Fig. 2a,b). The enthalpy of heme binding was
approximately −5 kcal mol−1, and the stoichiometry of heme to receptor binding was roughly
1:1. Thus, heme binding to the REV-ERB LBDs is fully reversible. Although the concentration
of heme in different tissues is not known, it has been suggested that they vary in a circadian
manner29, indicating that REV-ERBs might function as heme sensors.
Heme binding increases REV-ERB LBD thermal stability
Nuclear receptor ligands are generally lipophilic and increase protein thermal stability by
binding a hydrophobic central cavity in the LBDs. We examined the effect of heme binding
on thermal stability of the LBD by using circular dichroism spectroscopy. Heme binding
increased the melting temperature (Tm) of each LBD by 4–5 °C (Fig. 2c,d), consistent with
ligand effects on other nuclear receptor LBDs, for which it typically increases the Tm by 1–6
°C (refs. 30,31). These results suggested that a change in protein conformation occurs on heme
binding to REV-ERB LBDs, and this idea was supported by peptide interaction ‘conformation
sensing’ assays (Supplementary Fig. 6 and Supplementary Methods online).
Taken together, these data are consistent with the hypothesis that REV-ERBs act as
physiological sensors of heme concentrations in cells and that heme binding may act as the
molecular switch that regulates receptor conformation.
A REV-ERBα LBD mutant deficient in heme binding
Most heme binding proteins use histidine side chains to coordinate the heme molecule. In E75,
mutation of particular histidine or cysteine residue eliminates heme binding23,24, and some of
these residues are conserved in REV-ERBα and REV-ERBβ (Supplementary Fig. 1). We
individually mutated residues Cys389 (conserved in REV-ERBα and REV-ERBβ), and Cys418
and His602 (conserved in E75 and both REV-ERBs) in the LBD of REV-ERBα. All three
mutant LBDs were stable when expressed in E. coli and were purified for ITC analysis of their
ability to bind heme.
C389A and C418A showed affinities for heme similar to that of the wild-type LBD (data not
shown). By contrast, REV-ERBα LBD H602F showed substantially diminished affinity for
binding heme (Kd: wild type, 3.5 ± 0.2 μM; H602F, > 120 μM; Fig. 3). In addition, ultraviolet-
visible spectrum analysis indicated that the H602F mutant was not associated with heme (Fig.
3), implying that H602 is essential for heme binding to the REV-ERBα LBD.
Heme is required for the repressor activity of REV-ERBα LBD
To examine the role of heme in REV-ERBα function in cells, we assessed the transcriptional
repressor activity of REV-ERBα LBD and the H602F mutant, fused to the DNA-binding
domain (DBD) of Gal4 in both HuH7 hepatoma cells and HEK293 cells. Use of the Gal4 DBD
chimeric receptors facilitated direct assessment of the transcriptional repressor activity of the
LBDs in isolation.
Both fusions were expressed in similar amounts, as determined by immunoblotting
(Supplementary Fig. 7a online). There was, however, a complete loss in transcriptional
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repression activity of the H602F LBD, as compared with the wild-type LBD (Fig. 3), suggesting
that heme binding is required for repression.
Heme regulates the expression of REV-ERBα target genes
The lack of ability of the Gal4 DBD REV-ERBα LBD H602F mutant to repress transcription
suggested that heme might be required for the repressive effect of REV-ERBα on its target
genes. To test this idea, we modulated intracellular heme in human HepG2 hepatoblastoma
cells and examined the effects on the REV-ERBα target genes BMAL1 and ELOVL3. We
inhibited heme biosynthesis in cells with succinylacetone, a highly specific inhibitor of
aminolevulinic acid dehydratase that has been used to decrease intracellular heme in several
cell lines and in vivo32–37.
Although intracellular heme is usually tightly regulated, we effectively reduced intracellular
concentrations by about 40% using succinylacetone (Fig. 4a). This reduction was accompanied
by a 2.6-fold increase in the expression of ALAS1 (Fig. 4b), the gene encoding aminolevulinic
acid synthase. Because ALAS1 expression is known to be under negative transcriptional
feedback control by heme34, the observed upregulation of ALAS1 on succinylacetone treatment
indicates that the decrease in heme is physiologically significant. By contrast, addition of hemin
to the cells resulted in a significant (P < 0.05) 33% increase in intracellular heme (Fig. 4a),
accompanied by a 40% decrease in ALAS1 expression, again consistent with the physiological
response to an excess of intracellular heme. As an alternative to succinylacetone method, the
effect of inhibition of ALAS1 expression by short interfering RNA (siRNA) was also examined.
We found, however, that there was no correlation between inhibition of ALAS1 and a decrease
in intracellular heme (potentially owing to compensatory effects of heme oxygenase) and, as
a result, we did not pursue further the siRNA approach for modulation of heme.
In heme-depleted cells, we noted a significant (P < 0.05) increase in expression of BMAL1 (3-
fold) and ELOVL3 (5.5-fold; Fig. 4c,d). The increase in expression of REV-ERB target genes
that followed heme depletion was consistent with our data on the chimeric H602F LBD,
suggesting that an ability to bind heme is required for the repressor activity of REV-ERB LBD.
We expected that increasing intracellular heme would result in a decrease in expression of
REVERB target genes, owing to an increase in repressive activity. Indeed, raising intracellular
heme caused significant (P < 0.05) decreases in BMAL1 and ELOVL3 expression (Fig. 4c,d).
These data are consistent with our hypothesis that heme selectively regulates the transcription
of REV-ERB target genes.
Heme regulates NCoR recruitment to REV-ERBα
REV-ERBs repress the transcription of their target genes through recruitment of the co-
repressor NCoR38,39. The inability of the H602F REV-ERBα LBD mutant to repress
transcription, in addition to the observation that intracellular heme regulates the expression of
REV-ERBα target genes, suggests that heme may regulate the ability of REV-ERBα to interact
with NCoR. Consistent with this hypothesis, depleting intracellular heme resulted in a
decreased interaction of REV-ERBα with NCoR, as determined by co-immunoprecipitation.
(Fig. 5a). Addition of 30 μM hemin to the heme-depleted cells resulted in partial recovery of
the interaction between REV-ERBα and NCoR (Fig. 5b). Depletion of heme also resulted in
a large decrease in NCoR occupancy of the RORE in the BMAL1 promoter, as determined by
chromatin immunoprecipitation (ChIP) and quantitative PCR (Fig. 5b). Similar to the co-
immunoprecipitation results, addition of hemin to the heme-depleted cells resulted in partial
recovery of NCoR occupancy of the BMAL1 promoter (Fig. 5b). It should be noted that the co-
immunoprecipitation and ChIP studies were performed in HepG2 cells expressing endogenous
amounts of REV-ERBα and NCoR. These data indicate that heme can regulate the interaction
Raghuram et al. Page 4
Nat Struct Mol Biol. Author manuscript; available in PMC 2009 September 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of REV-ERBα with NCoR and are also consistent with the hypothesis that heme regulates
REV-ERB–mediated recruitment of NCoR to the BMAL1 promoter.
REV-ERB LBDs appear not to be redox or gas sensors
In other types of heme–protein complexes, the heme prosthetic group confers the ability to
respond either to alterations in redox state or to diatomic gases. We found that reduction of the
heme iron through the addition of 10 μM dithionite did not substantially change the binding
activity of the CoRNR box peptide, suggesting that the redox state of heme does not alter LBD
conformation (Supplementary Fig. 8a,b online). Addition of pharmacological nitric oxide
donors did not affect the transcriptional activity of the REV-ERB LBD (Supplementary Fig.
8a,b). Thus, in contrast to E75, REV-ERBs seem to be insensitive to the redox state and
diatomic gasses.
DISCUSSION
We have shown that heme meets the requirements of a physiological ligand for the human
orphan nuclear receptors REV-ERBα and REVERBβ. Heme binding took place in a 1:1
stoichiometry with the REVERB LBDs, as determined by ITC (Fig. 2a,b), and, consistent with
the role of heme as a REV-ERB ligand, the receptor LBDs underwent changes in thermal
stability and conformation on heme addition (Fig. 2c,d and Supplementary Fig. 6). Modulation
of intracellular heme resulted in a change in the expression of REV-ERB target genes (Fig. 4)
and in alteration of the interaction of REV-ERBα with NCoR (Fig. 5a). The effects of heme
were specific to the REV-ERB LBDs because we observed no effect on other nuclear receptors
such as LXR (Supplementary Fig. 6). These results are consistent with the idea that the REV-
ERBs function as physiological sensors of intracellular heme. The identification of a member
of the nuclear receptor superfamily as a heme receptor indicates that the diversity of
endogenous ligands for this superfamily is more extensive than the steroids, retinoids, thyroid
hormone and lipids identified so far. The affinity of heme for the REV-ERB LBDs (Kd ≈ 3
μM) suggests that these receptors belong in the category of physiological nuclear receptor
‘metabolite’ sensors, such as FXR (bile acids), LXR (oxysterols) and PPARs (fatty acids), for
which Kd values of 1–10 μM have been observed40.
Although the Drosophila E75 protein also associates with heme, there are many important
differences between E75 and the two human REV-ERB proteins characterized here. In
biochemical assays, the REV-ERB LBDs show reversible binding with heme and stability in
both the ligand-bound and apoprotein state (Supplementary Fig. 6). By contrast, binding of
heme to E75 seems to be constitutive and is required for protein stability23. We found that, in
the REV-ERB LBDs, a change in the oxidation state of the iron does seem to alter receptor
conformation (Supplementary Fig. 9a,b online). In addition, the transcriptional activity of the
REV-ERB does not seem to be responsive to diatomic gases. Thus, it seems that REV-ERBs
function as sensors of heme, rather than using heme to sense redox conditions or gases.
Variations in intracellular heme, which occur in a circadian manner in mammals25, may allow
REV-ERB proteins to modulate repression of their target genes and to shape appropriately the
amplitude of the circadian rhythm. REV-ERBα regulates the expression of several genes
involved in circadian pathways and in lipid metabolism and adipogenesis16,41–46. Our findings
indicate that the REV-ERBs sense and respond to dynamic changes in intracellular free heme
and may use heme to integrate the circadian clock and metabolic programs. Importantly, the
REV-ERB target gene BMAL1, an essential component of the circadian oscillator, is also
essential for adipogenesis47,48. Such links between circadian rhythms and metabolic patterns
have been recognized for some time19,48. More direct evidence has come from mice carrying
mutations in BMAL1 or Clock. These mice show abnormalities similar to metabolic syndrome
including obesity, dyslipidemia and impaired glucose metabolism49,50. Our finding that the
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REV-ERBs are in fact ligand-regulated receptors suggests that synthetic modulators of the
REV-ERB proteins may be developed in the future with the goal of treating human diseases
related to coordination of the cellular clock, control of glucose and energy metabolism.
Synthesis of heme, the ligand for the REV-ERBs, is linked to the nutritional status of mammals
through the regulation of ALAS1 by the nuclear receptor coactivator PGC-1α (ref. 51). This
coactivator is induced by fasting and mediates the transition from glucose to fatty acid use as
an energy source and has been shown to integrate the mammalian clock and energy
metabolism52. We predict that alterations in PGC-1α–induced expression of ALAS1, along
with the rate of heme synthesis, may provide a direct pathway for modulating REV-ERB–
mediated regulation of the circadian rhythm and energy metabolism, thereby serving as an
additional link between these two crucial and intricately regulated biological processes. Finally,
REV-ERBα is involved in the induction of adipogenesis, and we predict that heme has a crucial
role in this process. Indeed, heme has been shown to be essential in the induction of adipocyte
differentiation53, and our results suggest that this role of heme may be mediated by REV-ERB,
which also plays an important part in adipogenesis.
METHODS
Expression and purification of REV-ERBα and REV-ERBβ
For LBDs, residues 281–614 of REV-ERBα (NM_021724) and 247–579 of REV-ERBβ
(NM_005126) were expressed as 6×His-tagged proteins from a pET46 Ek/Lic vector in Rosetta
(DE3)-pLysS E. coli cells (Novagen). We added 150 μM 5-amino levulinic acid to the cultures
to enhance expression of the proteins. The cells were induced with 0.5 mM isopropyl-β-D-
thiogalactoside (IPTG) at 16 °C overnight, collected and lysed in 20 mM Tris (pH 8.0), 500
mM NaCl, 20 mM imidazole and 10% glycerol. The proteins were purified with His-Bind
Resin (Novagen) and eluted with 250 mM imidazole. The purified LBDs were dialyzed against
20 mM Tris, 200 mM NaCl and 5% glycerol for subsequent experiments. LBD concentrations
were estimated by using the calculated molar extinction coefficient (ε280) of 0.619 = 1 mg/ml
(for REV-ERBα) and 0.393 = 1 mg/ml (for REV-ERBβ). The bound heme concentration was
estimated by using the extinction coefficient for the heme Soret peak (ε415) of 101.85 = 1 mM.
For mammalian expression of full-length receptors, pCMV7.1_3X plasmids containing Flag-
tagged REV-ERBα and REV-ERBβ were transiently transfected into suspension-adapted 293-
EBNA cells (CRL-10852, ATCC; 10 l at 106 cells per ml). After 24 h, bovine hemin (H 5533,
Sigma-Aldrich) was added at 1 mg/l. After 48 h, cells were collected, frozen at −80 °C, and
lysed with Cell Lytic M buffer (Sigma-Aldrich). The proteins were purified by using a Flag
M2 affinity (Sigma) column and eluted with 3×Flag peptide (Sigma-Aldrich). The presence
of REV-ERBα and REV-ERBβ in the eluted fractions was assessed by immunoblotting using
a Flag M2 monoclonal antibody (Sigma-Aldrich). The presence of heme was determined by
the Soret band (415 nm).
Ultraviolet-visible spectroscopy
Soret and α,β absorption spectra were measured on a Cary 50 Bio ultraviolet-visible
spectrophotometer at room temperature (22 °C). To reduce the heme group, 10 mM sodium
hydrosulfite (dithionite) was added to the protein samples. Spectra of reduced complexes were
recorded 5 (for REV–ERBα) or 50 (for REV–ERBβ) min after the addition of 10 mM dithionite.
Mass spectrometry
The REV-ERBα and REV-ERBβ LBDs and the Flag-tagged full-length proteins were first
dialyzed against water to remove salt. Protein concentrations of 0.5–1 mg/ml were used for
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MALDI mass spectrometry analyses. The samples were analyzed at the Biomolecular Facility
of the University of Virginia as described in the Supplementary Methods.
ITC
We carried out ITC experiments at 20 °C on a MicroCal VP-ITC instrument. For heme binding
studies, LBDs were dialyzed extensively against 20 mM Tris (pH 8.0), 200 mM NaCl and 5%
glycerol, and then concentrated in the same buffer to 0.050 mM (REV-ERBα) or 0.045 mM
(REV-ERBβ). The concentration of hemin solution in the ITC binding studies was 0.466 mM
(for REV-ERBα) or 0.561 mM (for REV-ERBβ).
Circular dichroism
Purified LBDs were dialyzed against 10 mM NaH2PO4 (pH 7.5) and 50 mM NaCl.
Measurements were carried out on an AVIV circular dichroism instrument. For temperature
melting experiments, a gradient of 20–70 °C was used with 2 °C jumps and a 2-min
equilibration time. The change in circular dichroism signal was measured at 223 nm and 224
nm for REV-ERBα and REV-ERBβ, respectively. Protein concentrations were 0.4 mg/ml.
Similar measurements were repeated after the addition of 50 μM hemin to the protein
samples54.
Measurement of cellular heme content
Heme in HepG2 cell lysates was measured by using a modified QuantiChrom Heme Assay
(BioAssay Systems). The amount of heme in each sample is expressed as μM heme per mg of
total protein.
Manipulations of heme biosynthesis
Succinylacetone (Sigma) was added to confluent HepG2 cultures at a final concentration of
0.5 mM (ref. 32) for 24 h before cell collection. We added 30 μM hemin (Sigma) to confluent
cultures for 24 h before cell collection as described55. Hemin was added either in the absence
of succinylacetone (Fig. 4) or in the presence of succinylacetone (simultaneous treatment; Fig.
5).
Quantitative RT-PCR
Quantitative RT-PCR was performed as described56. The BMAL1 (NM_001178) primers were
(5′-GTACCAACATGCAACGCAATG-3′) and (5′-TGTGTATGGATTGGTGGCACC-3′).
Cyclophilin B (M60857) was used as a standard with the following primers: (5′-
GGAGATGGCACAGGAGGAAA -3′) and (5′-
CGTAGTGCTTCAGTTTGAAGTTCTCA-3′). ELOVL3 primers were obtained from
Superarray.
ChIP assay
ChIP assays were performed as described38,57. Chromatin-immunoprecipitated DNA was
quantified by quantitative PCR with the following primers specific to the human BMAL1
promoter: BMAL1_prom-for (5′-ATTGGTGGCAGGAAAGTAGC-3′) and BMAL1_prom-
rev (5′-GTTGTGTGGCGGCTAGAGAG-3′).
Co-immunoprecipitation assay
HepG2 cells were treated with succinylacetone (2 mM) or both succinylacetone (2 mM) and
hemin (30 μM) for 24 h before immunoprecipitation. Cells were lysed in Triton lysis buffer
(20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 1.5
mM MgCl2, 1 mM dithiothreitol, 1 mM phenylmethylsulphonyl fluoride, 10 mg/ml of aprotinin
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and 10 mg/ml of leupeptin). Protein concentrations were measured with BCA Protein Assay
Reagent (Pierce) and ~0.5 mg of protein lysate was used for each immunoprecipitation. The
antibodies used for immuno-precipitation and immunoblotting were anti–REV-ERBα (Cell
Signaling Technologies) and anti–NCoR C-20 (Santa Cruz Biotechnology).
Co-transfection and reporter assays
HuH7 and HEK293 cells were seeded in 96-well plates at 25,000 cells per well as
described58 with the modifications outlined in the Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Association of heme with the LBDs from REV-ERBα and REVERBβ. (a) MALDI mass
spectra showing iron protoporphyrin IX in purified REV-ERBα and REV-ERBβ LBDs
prepared from E. coli. Signals at 616 ± 2 Da correspond to heme iron-protoporphyrin IX. (b)
Visible absorption spectra of REV-ERB LBD proteins. Peaks characteristic of heme–protein
complexes are shown in the 390–450 nm range for the Soret band and in the 500–580 nm range
for the α and β bands. Red spectra correspond to the heme–protein complexes after dithionite
reduction of the iron moiety.
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Figure 2.
Thermodynamics of heme association with the REV-ERB LBDs measured by ITC and circular
dichroism spectroscopy. (a,b) ITC data corresponding to the REV-ERBα (a) and REV-ERBβ
(b) LBDs binding hemin. (c,d) Far-ultraviolet circular dichroism thermal melts corresponding
to the REV-ERBα (c) and REV-ERBβ (d) LBDs in the heme-bound (+heme) and apoprotein
(−heme) forms. The Tm values are 48.6 °C (−heme) and 52.9 °C (+heme) for REV-ERBα LBD
and 48.4 °C (−heme) and 53.3 °C (+heme) for REV-ERBβ LBD.
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Figure 3.
Role of heme in regulation of REV-ERBα LBD activity. (a) Ultraviolet-visible spectrum of
wild-type REV-ERBα (blue) and H602F REV-ERBα (red) LDBs. The absorbance peaks at
280 nm indicate that similar amounts of wild-type and H602F protein were examined, whereas
the loss of the absorbance peak at ~420 nm for the H602F protein indicates lack of heme
binding. (b) Lack of heme binding by the H602F REV-ERBα LBD mutant determined by ITC.
Minimal binding to heme was not saturable; thus, Kd could not be estimated (c) Co-transfection
reporter assay, comparing the transcriptional activity of the wild-type and H602F REV-
ERBα LBDs fused to the Gal4 DBD in HuH7 hepatoma cells and HEK293 cells. The cells
were co-transfected with a vector containing five copies of the Gal4 UAS upstream of luciferase
(5×UAS-SV40 pGL3 firefly luciferase reporter vector). The wild-type and H602F chimeric
proteins were expressed in comparable amounts, as determined by immunoblotting
(Supplementary Fig. 8). Experiments were performed in triplicate a minimum of three times,
and the mean ± s.d. of a representative experiment is shown.
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Figure 4.
Effect of modulation of intracellular heme on expression of REV-ERB target genes in HepG2
cells. (a) Treatment of HepG2 cells with succinylacetone (−heme) results in depletion of
intracellular heme, whereas addition of hemin results in an increase in intracellular heme
(+heme). (b) Expression of ALAS1 increases in response to a decrease in intracellular heme,
and decreases in response to an increase in intracellular heme. (c,d) Expression of BMAL1
(c) and ELOVL3 (d) increases with heme depletion and decreases with increased intracellular
heme; both genes are known to be repressed by REV-ERBα. Data are the mean ± s.d. of
triplicate wells. *P < 0.05.
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Figure 5.
Effect of intracellular heme on NCoR interaction with REV-ERBα and recruitment to
promoters. (a) The interaction of REV-ERBα with NCoR in HepG2 cells was determined by
coimmunoprecipitation. Heme was depleted by succinylacetone treatment (−heme), and added
back (+heme) by supplying hemin to heme-depleted cells. Cellular extracts were
immunoprecipitated with antibody to NCoR, and samples were analyzed by immunoblotting
with an antibody to REV-ERBα. Experiments were performed a minimum of three times and
a representative gel is shown (top). Use of IgG did not result in detectable REV-ERBα
(Supplementary Fig. 7b). Histogram shows quantification of the REV-ERBα immunoblots
(bottom). Data are the mean ± s.d. from three individual experiments. Student’s t-test: *P <
0.05 versus control, **P < 0.05 versus heme depletion. (b) Effect of intracellular heme on
NCoR occupancy in the BMAL1 promoter in HepG2 cells. Heme was depleted by
succinylacetone treatment (−heme), and added back by hemin supplementation to heme-
depleted cells (+heme). Chromatin was immunoprecipitated with an antibody to NCoR, and
DNA was quantified by quantitative PCR. A control using rabbit IgG was used for
normalization. Histogram shows the results from a representative of three independent
experiments.
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